UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
January 07, 2020
(Commission File No. 001-38475)
ASLAN PHARMACEUTICALS LIMITED
(REG. NO. 289175)
(Translation of registrant’s name into English)
CAYMAN ISLANDS
(Jurisdiction of incorporation or organisation)
83 CLEMENCEAU AVENUE
#12-03 UE SQUARE
SINGAPORE 239920
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):
Yes ☐ No ☒
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):
Yes ☐ No ☒
Announcement of the Board resolution convening the first Extraordinary Shareholders’ Meeting of 2020
|
|
1. |
Date of the board of directors resolution: 01/06/2020 |
|
|
2. |
Date for convening the extraordinary shareholders' meeting: 02/26/2020 |
|
|
3. |
Location for convening the extraordinary shareholders' meeting: |
Taipei International Convention Center, Room 105
(No. 1, Sec. 5, Xinyi Rd., Xinyi Dist., Taipei City, Taiwan, R.O.C.)
|
|
4. |
Cause or subjects for convening the meeting (1) Report Items: |
Implementation status of the Company’s prior private placements proposals.
|
|
5. |
Cause or subjects for convening the meeting (2) Matters for Ratification: |
None.
|
|
6. |
Cause or subjects for convening the meeting (3) Matters for Discussion: |
|
|
(a) |
To conduct capital increase by issuance of ordinary shares for sponsoring overseas depositary receipts or by issuance of the ordinary shares of the Company domestically |
|
|
(b) |
To conduct capital increase by issuance of ordinary shares or overseas depositary receipts by private placement |
|
|
7. |
Cause or subjects for convening the meeting (4) Elections: None. |
|
|
8. |
Cause or subjects for convening the meeting (5) Other Proposals: None. |
|
|
9. |
Cause or subjects for convening the meeting (6) Extemporary Motions: None. |
|
|
10. |
Book closure starting date: 01/28/2020 |
|
|
11. |
Book closure ending date: 02/26/2020 |
|
|
12. |
Any other matters that need to be specified: |
The voting rights at this EGM may be exercised by means of electronic transmission, the exercise period starts from 8 February 2020 through 23 February 2020. Shareholders should access the designated platform of electronic voting for instructions. (link to: https://www.stockvote.com.tw).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
|
|
|
|
ASLAN PHARMACEUTICALS LIMITED |
|
|
(Registrant) |
|
|
|
|
|
By: |
/s/ Kiran Kumar Asarpota
|
|
Name: |
Kiran Kumar Asarpota |
|
Title: |
VP Finance |
Date: January 07, 2020